ProDiGe: PRioritization Of Disease Genes with multitask machine learning
  from positive and unlabeled examples by Mordelet, Fantine & Vert, Jean-Philippe
ar
X
iv
:1
10
6.
01
34
v1
  [
q-
bio
.Q
M
]  1
 Ju
n 2
01
1
ProDiGe: PRioritization Of Disease Genes with multitask machine
learning from positive and unlabeled examples
Fantine Mordelet1,2,3,4 and Jean-Philippe Vert1,2,3
1Mines ParisTech, Centre for Computational Biology, Fontainebleau, F-77300, France
2 Institut Curie, Paris, F-75248 France
3 INSERM, U900, Paris, F-75248 France
4 CREST, INSEE, Malakoff, F-92240 France
fantinemordelet@gmail.com jean-philippe.vert@mines.org
October 1, 2018
Abstract
Elucidating the genetic basis of human diseases is a central goal of genetics and molecular biology.
While traditional linkage analysis and modern high-throughput techniques often provide long lists of
tens or hundreds of disease gene candidates, the identification of disease genes among the candidates
remains time-consuming and expensive. Efficient computational methods are therefore needed to
prioritize genes within the list of candidates, by exploiting the wealth of information available about
the genes in various databases. Here we propose ProDiGe, a novel algorithm for Prioritization of
Disease Genes. ProDiGe implements a novel machine learning strategy based on learning from positive
and unlabeled examples, which allows to integrate various sources of information about the genes, to
share information about known disease genes across diseases, and to perform genome-wide searches for
new disease genes. Experiments on real data show that ProDiGe outperforms state-of-the-art methods
for the prioritization of genes in human diseases.
Introduction
During the last decades, considerable efforts have been made to elucidate the genetic basis of rare and
common human diseases. The discovery of so-called disease genes, whose disruption causes congenital
or acquired disease, is indeed important both towards diagnosis and towards new therapies, through
the elucidation of the biological bases of diseases. Traditional approaches to discover disease genes first
identify chromosomal regions likely to contain the gene of interest, e.g., by linkage analysis or study of
chromosomal aberrations in DNA samples from large case-control populations. The regions identified,
however, often contain tens to hundreds of candidate genes. Finding the causal gene(s) among these
candidates is then an expensive and time-consuming process, which requires extensive laboratory experi-
ments. Progresses in sequencing, microarray or proteomics technologies have also facilitated the discovery
of genes whose structure or activity are modified in disease samples, on a full genome scale. However,
again, these approaches routinely identify long lists of candidate disease genes among which only one or a
few are truly the causative agents of the disease process, and further biological investigations are required
to identify them. In both cases, it is therefore important to select the most promising genes to be further
studied among the candidates, i.e., to prioritize them from the most likely to be a disease gene to the
less likely.
Gene prioritization is typically based on prior information we have about the genes, e.g., their bi-
ological functions, patterns of expression in different conditions, or interactions with other genes, and
follows a “guilt-by-association” strategy: the most promising candidates genes are those which share
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similarity with the disease of interest, or with other genes known to be associated to the disease. The
availability of complete genome sequences and the wealth of large-scale biological data sets now provide
an unprecedented opportunity to speed up the gene hunting process [1]. Integrating a variety of het-
erogeneous information stored in various databases and in the literature to obtain a good final ranking
of hundreds of candidate genes is, however, a difficult task for human experts. Unsurprisingly many
computational approaches have been proposed to perform this task automatically via statistical and data
mining approaches. While some previous works attempt to identify promising candidate genes without
prior knowledge of any other disease gene, e.g., by matching the functional annotations of candidate
genes to the disease or phenotype under investigation [2–4], many successful approaches assume that
some disease genes are already known and try to detect candidate genes which share similarities with
known disease genes for the phenotype under investigation [5–10] or for related phenotypes [5, 9, 11–14].
These methods vary in the algorithm they implement and in the data they use to perform gene prioritiza-
tion. For example, Endeavour and related work [6,7,10] use state-of-the-art machine learning techniques
to integrate heterogeneous information and rank the candidate genes by decreasing similarity to known
disease genes, while PRINCE [14] uses label propagation over a protein-protein interaction (PPI) network
and is able to borrow information from known disease genes of related diseases to find new disease genes.
We refer the reader to [15] for a recent review of gene prioritization tools available on the web.
Here we propose ProDiGe, a new method for prioritization of disease genes based on the guilt-by-
association concept. ProDiGe assumes that a set of gene-disease associations is already known to infer
new ones, and brings three main novelties compared to existing methods. First, ProDiGe implements a
novel machine learning paradigm to score candidate genes. While existing methods like those of [6,7,10]
score independently the different candidate genes in terms of similarity to known disease genes, ProDiGe
exploits the relative similarity of both known and candidate disease genes to jointly score and rank all
candidates. This is done by formulating the disease gene prioritization problem as an instance of the
problem known as learning from positive and unlabeled examples (PU learning) in the machine learning
community, which is known to be a powerful paradigm when a set of candidates has to be ranked in terms
of similarity to a set of positive data [16–18]. Second, in order to rank candidate genes for a disease of
interest, ProDiGe borrows information not only from genes known to be associated to the disease, but
also from genes known to play a role in diseases or phenotypes related to the disease of interest. This
again differs from [6,7,10] which treat diseases independently from each other. It allows us, in particular,
to rank genes even for orphan diseases, with no known gene, by relying only on known disease genes of
related diseases. In the machine learning jargon, we implement a multi-task strategy to share information
between different diseases [19–21], and weight the sharing of information by the phenotypic similarity of
diseases. Third, ProDiGe performs heterogeneous data integration to combine a variety of information
about the genes in the scoring function, including sequence features, expression levels in different condi-
tions, PPI interactions or presence in the scientific literature. We use the powerful framework of kernel
methods for data integration [22–24], akin to the work of [6,7,10]. This differs from approaches like that
of [14], which are limited to scoring over a gene or protein network.
We test ProDiGe on real data extracted from the OMIM database [25]. It is able to rank the correct
disease gene in the top 5% of the candidate genes for 69% of the diseases with at least one other known
causal gene, and for 67% of the diseases when no other disease genes is known, outperforming state-of-
the-art methods like Endeavour and PRINCE.
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Results
Gene prioritization without sharing of information across diseases
We first assess the ability of ProDiGe to retrieve new disease genes for diseases with already a few known
disease genes, without sharing information across different diseases. As a gold standard we extracted all
known disease-gene associations from the OMIM database [25], and we borrowed from [7] nine sources
of information about the genes, including expression profiles in various experiments, functional anno-
tations, known protein-protein interactions (PPI), transcriptional motifs, protein domain activity and
literature data. Each source of information was encoded in a kernel functions, which assesses pairwise
similarities between each pair of genes according to each source of information. We compare two ways
to perform data integration: first by simply averaging the nine kernel functions, and second by letting
ProDiGe optimize itself the relative contribution of each source of information when the model is esti-
mated, through a multiple kernel learning (MKL) approach. We compare both variants with the best
model of [10], namely, the MKL1Class model which differs from ProDiGe in this case only in the machine
learning paradigm implemented: while ProDiGe learns a model from positive and unlabeled examples,
MKL1class learns it only from positive examples. We tested these three algorithm in a leave-one-out
cross-validation (LOOCV) setting. In short, for each disease, each known disease gene was removed in
turn, a model was trained on using the remaining disease genes as positive examples, and all 19540 genes
in our database were ranked; we then recorded the rank of the positive gene that was removed in this
list. We focused on the 285 diseases in our dataset having at least 2 known disease genes, because all
three methods require at least one known disease gene for training, and for the purpose of LOOCV we
need in addition one known disease gene removed from the training set.
Figure 1 presents the cumulative distribution function (CDF) of the rank of the left-out positive gene,
i.e., the number of genes that were ranked in the top k genes of the list as a function of k, for each
method. Note that the rank is always between 1 (best prediction) and 19540−|P |, where |P | is the num-
ber of genes known to be associated to the disease of interest. The right panel zooms on the beginning
of this curve which corresponds to the distribution of small values of the rank. We see clearly that both
ProDiGe variants outperform MKL1class in the sense that they consistently recover the hidden positive
gene at a better rank in the list. A Wilcoxon signed rank test confirms these visual conclusions at 5%
level with P-values 6.1e−29 and 8.8e−28, respectively, for the average and MKL variants of ProDiGe. This
illustrates the benefits of formulating the gene ranking problem as a PU learning problem, and not as a
1-class learning one, since apart from this formulation both MKL1Class and ProDiGe1 use very similar
learning engines, based on SVM and MKL.
Both ProDiGe1 variants recover roughly one third of correct gene-disease associations in the top 20
genes among almost 19540, i.e., in the top 0.1%. However, we found no significant difference between
the mean and MKL variants of ProDiGe in this setting (P-value=0.619). This means that in this case,
assigning equal weights to all data sources works as well as trying to optimize these weights by MKL.
Supported by this result and by the fact that MKL is much more time-consuming than a SVM with the
mean kernel, we decided to restrict our experiments to the mean kernel in the following experiments.
Gene prioritization with information sharing across diseases
In a second run of experiments, we assess the performance of ProDiGe when it is allowed to share in-
formations across diseases. We tested three variants of ProDiGe, as explained in Material and Methods:
ProDiGe2, which uniformly shares information across all diseases without using particular informations
about the diseases, ProDiGe3, which weights the sharing of informations across diseases by a phenotypic
similarity between the diseases, and ProDiGe4, a variant of ProDiGe3 which additionally controls the
3
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Figure 1: Cumulative distribution function of the rank for local methods, in the LOOCV
experiment. ProDiGe1-Mean and ProDiGe1-MKL refer to the ProDiGe1 variant combined with the
mean kernel or the MKL strategy to fuse heterogeneous gene information. Panel (A) Global curve, Panel
(B) Zoom on the beginning of the curve.
sharing of information between diseases that would have very similar phenotypic description but which
remain different diseases. All variants are based on the same methodological backbone, namely, the use
of a multitask learning strategy, and only differ in a function used to control the sharing of information.
We limit ourselves to the 1873 diseases in the disease-gene association dataset which were also in the
phenotypic similarity matrix that we used. This corresponds to a total of 2544 associations between these
diseases and 1698 genes. We compare these variants to PRINCE [14], a method recently proposed to
rank genes by sharing information across diseases through label propagation on a PPI network.
Figure 2 shows the CDF curves for the four methods. Comparing areas under the global curve, i.e.,
the average rank of the left-out disease gene in LOOCV, the four methods can be ranked in the fol-
lowing order: ProDiGe4 (1682) > ProDiGe3 (1817) > ProDiGe2 (2246) > PRINCE (3065). The fact
that ProDiGe3 and ProDiGe4 outperform ProDiGe2 confirms the benefits of exploiting prior knowledge
we have about the disease phenotypes to weight the sharing of information across diseases, instead of
following a generic strategy for multitask learning. The fact that ProDiGe4 outperforms ProDiGe3 is
not surprising and illustrates the fact that the diseases are not fully characterized by the phenotypic
description we use. Zooming to the beginning of the curves (right picture), we see that the relative order
between the methods is conserved except for PRINCE which outperforms ProDiGe2 in that case. In fact,
ProDiGe2 has a very low performance compared to all other methods for low ranks, confirming that the
generic multitask strategy should not be pursued in practice if phenotypic information is available.
The fact that ProDiGe3 and ProDiGe4 outperform PRINCE for all rank values confirm the compet-
itiveness of our approach. On the other hand, the comparison with PRINCE is not completely fair since
ProDiGe exploits a variety of data sources about the genes, while PRINCE only uses a PPI network. In
order to clarify whether the improvement of ProDiGe over PRINCE is due to a larger amount of data
used, to the learning algorithm, or to both, we ran ProDiGe3 with only the kernel derived from the PPI
network which we call ProDiGe-PPI in Figure 2. In that case, both ProDiGe and PRINCE use exactly
the same information to rank genes. We see on the left picture that this variant is overall comparable to
PRINCE (no significant difference between PRINCE and ProDiGe-PPI with a Wilcoxon paired signed
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rank test), confirming that the main benefit of ProDiGe over PRINCE comes from data integration. In-
terestingly though, at the beginning of the curve (right picture), ProDiGe-PPI is far above PRINCE, and
even behaves comparably to the best method ProDiGe4. Since ProDiGe-PPI and PRINCE use exactly
the same input data, this means that the better performance of ProDiGe-PPI for low ranks comes from
the learning method based on PU learning with SVM, as opposed to label propagation over the PPI
network.
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Figure 2: Cumulative distribution function of ranks in the LOOCV experiments, for global
approaches . ProDiGe2, 3, 4 refer to the three variants of ProDiGe which share information, while
ProDiGe-PPI refers to ProDiGe3 trained only the PPI network data. Panel (A) Global curve. Panel (B)
Zoom on the beginning of the curve.
To better visualize the differences between the different variants of ProDiGe, the scatter plots in Figure
3 compare directly the ranks obtained by the different variants for each of the 2544 left-out associations.
Note that smaller ranks are better than large ones, since the goal is to be ranked as close as possible to
the top of the list. On the left panel, we compare ProDiGe3 to ProDiGe4. We see that many points are
below the diagonal, meaning that adding a Dirac kernel to the Phenotype kernel (ProDiGe4) generally
improves the performance as compared to using a Phenotype kernel (ProDiGe3) alone. On the right
panel, the ProDiGe2 is compared to the ProDiGe3. We see that the points are more concentrated above
the diagonal, but with large variability on both sides of the diagonal. This indicates a clear advantage
in favor of the Phenotype kernel compared to the generic Multitask kernel, although the differences are
quite fluctuant.
Is sharing information across diseases beneficial?
In order to check whether sharing information across diseases is beneficial, we restrict ourselves to diseases
with phenotypic informations and with at least two known associated genes in the OMIM database. This
way, we are able to share information across diseases and, at the same time, to run methods that do not
share information because we ensure that there is at least one training gene in the LOOCV procedure.
This leaves us with 265 diseases, corresponding to 936 associations.
Figure 4 shows the CDF curves of the rank for the various methods on these data, including the
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Figure 3: Comparison of rank measures between different variants of ProDiGe. Each point
represent a disease-gene association. We plot the rank they obtain from the different methods when they
are left out in the LOOCV procedure. Small rank are therefore better than large ranks.
two methods MKL1class and ProDiGe1 (with the mean kernel for data integration), which do not share
information across diseases, and ProDiGe 2, 3, 4 and PRINCE, which do share information. Interestingly,
we observe different retrieval behaviors on these curves, depending on the part of the curve we are inter-
ested in. On the one hand, if we look at the curves globally, ProDiGe 4 and 3 perform very well, having
high area under the CDF curve, i.e., a low average rank (respectively 1529 and 1770). PRINCE and
MKL1class have the worse average ranks (respectively 3220 and 3351). A systematic test of differences
between the methods, using a Wilcoxon paired signed rank test over the ranks for each pair of methods,
is summarized in Figure 5 . In this picture, an arrow indicates that a method is significantly better than
another at level 5%. This confirms that ProDiGe 4 is the best method, significantly better than all other
ones except ProDiGe 1. Three variants of ProDiGe are significantly better than PRINCE and MKL1Class.
On the other hand, in the context of gene prioritization, it is useful to focus on the beginning of the
curve and not on the full CDF curves. Indeed, only the top of the list is likely to deserve any serious
biological investigation. Therefore we present a zoom of the CDF curve in panel (B) of Figure 4 . We see
there that the local methods ProDiGe1 and MKL1class present a sharper increase at the beginning of
the curve than the global methods, meaning that they yield more often truly disease genes near the very
top of the list than other methods. Additionally, we observe that ProDiGe1 is in fact the best method
when we focus on the proportion of disease genes correctly identified in up to the top 350 among 19540,
i.e., in up to the top 1.8% of the list. These results are further confirmed by the quantitative values in
Table 1, which show the recall (i.e., CDF value) as a function of the rank. ProDiGe 1, which does not
share information across diseases, is the best when we only focus at the very top of the list (up to the
top 1.8%), while ProDiGe 4, which shares information, is then the best method when we go deeper in
the list.
At this point it is interesting to question what position in the list we are interested in. In classical
applications where we start from a short list of, say, 100 candidates, then being in the top 5% of the
list means that the correct gene is ranked in the top 5 among the 100 candidates, while the top 1%
corresponds to the first of the list (see the last 3 columns of table 1). If we only focus on the first
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top 1 top 10 top 1% top 5% top 10%
MKL1class 11.5 25.3 41.1 52.8 59.9
ProDiGe1 12.3 27.8 49.2 61.9 71.2
ProDiGe2 0.1 0.7 17.8 51.2 66.9
ProDiGe3 1.9 11.4 38.6 64.0 74.2
ProDiGe4 3.1 14.6 43.4 68.9 78.4
PRINCE 1.5 6.8 37.3 57.1 65.4
Table 1: Recall of different methods at different rank levels, for diseases with at least one
known disease gene. The recall at rank level k is the percentage of disease genes that were correctly
ranked in the top k candidate genes in the LOOCV procedure, where the number of candidate genes is
near 19540. Top 1 and top 10 (first two columns) correspond respectively to the recall at the first and
first ten genes among 19540, while top X% (last three columns) refer to the recall at the first X% genes
among 19540.
gene of a short list of 100 candidates, then ProDiGe1 is the best method, with almost half of the genes
(49.2%) found in the first position, followed by ProDiGe4 (43.4%) and MKL1class (41.1%). As soon
as we accept to look further than the first place only, ProDiGe 4 is the best method, with 68.9% of
disease genes in the top 5 of a list of 100 candidates, for example. On the other hand, if we consider
a scenario where we start from no short list of candidates, and directly wish to predict disease genes
among the 19540 human genes, then only the few top genes in the list are interesting (see the first 2
columns of table 1). In that case, the methods that do not share information are clearly preferable, with
27.8% (resp 25.3%) of genes correctly found in the top 10 among 19540 for ProDiGe 1 (resp. MKL1class).
In summary, sharing information is not beneficial if we are interested only in the very top of the
list, typically the top 10 among 19540 candidates. This setting is however very challenging, where even
the best method ProDiGe1 only finds 12.3% of all disease genes. As soon as we are interested in more
than the top 2% of the list, which is a reasonable level when we start from a short list of a few tens or
hundreds of candidate genes, sharing information across diseases becomes interesting. In all cases, some
variant of ProDiGe outperforms existing methods. In particular ProDiGe4, which shares information
using phenotypic information across diseases while keeping different diseases distinct, is the best way to
share information.
Predicting causal genes for orphan diseases
Finally, we investigate the capacity of the different gene prioritization methods to identify disease genes
for orphan diseases, i.e., diseases with no known causative gene yet. ProDiGe1 and MKL1class, which
treat diseases independently from each other and require known disease genes to find new ones, can not be
used in this setting. Methods that share information across diseases, i.e., ProDiGe2, 3, 4 and PRINCE,
can be tested in this context, since they may be able to discover causative genes for a given orphan
diseases by learning from causative genes of other diseases. In fact, ProDiGe3 and ProDiGe4 boil down
to the same method in this context, because the contribution of the Dirac kernel in (6) vanishes when
no known disease gene for a disease of interest is available during training. We summarize them by the
acronym ProDiGe3-4 below.
To simulate this setting, we start from the 1608 diseases with only one known disease gene in OMIM
and phenotypic information, resulting in 1608 disease-gene associations involving 1182 genes. For each
disease in turn, the associated gene is removed from the training set, a scoring function is learned from
7
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Figure 4: Cumulative distribution function of ranks for local and multitask approaches. (A)
Global curve. (B) Zoom on the beginning of the curve.
Figure 5: Wilcoxon paired signed rank tests for significant rank difference between all
methods. ProDiGe1 and MKL1class are the only local approaches, which do not share information
across diseases. The number in each ellipse is the average rank obtained by the method in the LOOCV
procedure. An arrow indicates that a method is significantly better than another.
the associations involving other diseases, and the removed causal gene is ranked for the disease of interest.
We compute the rank of the true disease gene, and repeat this operation for each disease in turn. Figure
6 and Table 2 show the performance of the different global methods in this setting. Interestingly, they are
very similar to the results obtained in the multitask setting (Figure 2 and Table 1), both in relative order
of the methods and in their absolute performance. Overall, ProDiGe3-4 performs best, retrieving the true
causal gene in the top 10 genes of the list 13.1% of times, and in the top 5% of candidate genes 66.9%
of times. This is only slightly worse than the performance reached for diseases with known disease genes
(respectively 14.6% and 68.9%), highlighting the promising ability of global approaches to deorphanize
diseases.
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Figure 6: Cumulative distribution function of ranks for prioritization of causal genes for
orphan diseases. Panel (A) Global curve. Panel (B) Zoom on the beginning of the curve.
top 1 top 10 top 1% top 5% top 10%
ProDiGe2 0.1 1.4 16.8 50.4 68.1
ProDiGe3-4 1.9 13.1 42.7 66.9 76.1
PRINCE 0.5 4.8 36.9 52.9 60.6
Table 2: Recall of different methods at different rank levels, for orphan diseases. In this
case, since the disease has no known causal genes, only the causal genes of other diseases intervene in the
learning, meaning that ProDiGe3 and 4 are equivalent approaches.
Validation on selected diseases
To further validate ProDiGe, we used the whole training set to prioritize the unlabeled genes for a few
particular diseases with ProDiGe4. We completed the training set with a list of genes collected through
the use of Ingenuity Pathways Analysis (IPA, Ingenuity Systems). In Table 3, we report the results of
this validation for a first set of diseases having a training set of positive genes of reasonable size (more
than 11 genes). These diseases are in the same order: prostate cancer [MIM 176807], colorectal cancer
[MIM 114500], diabetes mellitus [MIM 125853], Alzheimer [MIM 104300], gastric cancer [MIM 137215],
leukemia acute myeloid [MIM 601626], breast cancer [MIM 114480], schizophrenia [MIM 181500]. The
columns report successively the disease name, the MIM id of the disease, the size of the training set, the
size of the intersection between the training set and the Ingenuity list, the estimated precision and recall
of the top 100 genes in the prioritized list and the p-value of a hypergeometric test. The precision is
estimated as the fraction of the top 100 genes that are also in the IPA list while recall is the fraction of
the IPA list that intersects the top 100 genes of the prioritized list. Of course, the true precision value
is unknown and the value we report underestimates the true value. The hypergeometric test allows to
test for the enrichment of the top 100 genes of our prioritized list in genes known to be associated to the
disease, which were not in the training set (namely genes previously extracted from IPA). We can see
that precision is good, except for schizophrenia, gastric cancer and leukemia. Recall on the other hand
9
is not very high but the values are limited by the large size of IPA lists. All tests are significant at 5% level.
Disease name MIM Id Training set Training
⋂
IPA Precision (%) Recall (%) P-value
Prostate cancer 176807 12 12 41 7.5 5.3e−40
Colorectal cancer 114500 17 17 51 5.7 7.3e−44
Diabetes mellitus 125853 26 22 21 1.4 2.1e−06
Alzheimer 104300 11 10 23 2.3 3.8e−11
Gastric cancer 137215 12 12 16 7.1 9.3e−16
Leukemia acute myeloid 601626 17 16 13 10.0 2.8e−15
Breast cancer 114480 19 16 33 3.7 6.4e−22
Schizophrenia 181500 17 11 6 3.2 4.5e−05
Table 3: Prioritization with ProDiGe4 for 8 diseases with a large training set of known genes.
The results were validated by comparing our top 100 genes with a list of genes related to the disease,
extracted from Ingenuity database.
We then did the same for 8 diseases with only 2 known genes in our training set: glaucoma [MIM
606657], Creutzfeld-Jacob [MIM 123400], hyperparathyroidism [MIM 145000], psoriasis [MIM 177900],
glioblastoma [MIM 137800], cystic fibrosis [MIM 219700], pancreatic carcinoma [MIM 260350], tha-
lassemia [MIM 604131]. Results are given in Table 4. As expected, precision is much smaller for these
diseases. However, we see that sharing information across diseases still allows to retrieve new disease
genes for diseases where the training set is very small.
Disease name MIM Id Training
⋂
IPA Precision (%) Recall (%) P-value
Glaucoma 606657 2 8 12.5 2.0e−11
Creutzfeld-Jacob 123400 2 2 40.0 1.3e−06
Hyperparathyroidism 145000 2 3 18.7 1.1e−06
Psoriasis 177900 2 4 6.0 1.8e−05
Glioblastoma 137800 2 16 10.7 8.4e−19
Cystic fibrosis 219700 2 5 10.6 9.3e−08
Pancreatic carcinoma 260350 1 8 9.6 2.3e−10
Thalassemia 604131 0 2 25.0 2.6e−06
Table 4: Prioritization with ProDiGe4 for 8 diseases with only 2 known genes. The results
were validated by comparing our top 100 genes with a list of genes related to the disease, extracted from
Ingenuity database.
Further validation include Table 5 which reports the top ten genes of the prioritized list for prostate
cancer, colorectal cancer, diabetes mellitus, Alzheimer, gastric cancer, leukemia acute myeloid, breast
cancer, schizophrenia. These lists were analyzed with GeneValorization [26], a text-mining tool for
automatic bibliography search.
Discussion
We have introduced ProDiGe, a new set of methods for disease gene prioritization. ProDiGe integrates
heterogeneous information about the genes in a unified PU learning strategy, and is able to share infor-
mation across different diseases if wanted. We have proposed in particular two flavours for disease gene
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ranking: ProDiGe1, which learns new causal genes for each disease separately, based on already known
causal genes for each disease, and ProDiGe4, which additionally transfers information about known dis-
ease genes across different diseases, weighting information sharing by disease phenotypic similarity. We
have demonstrated the efficiency of both variants on real data from the OMIM database where they
outperform Endeavour and PRINCE, two state-of-the-art gene prioritization methods.
A particularity of ProDiGe is the possibility to encode prior knowledge on disease relatedness through
the disease kernel. While a Dirac kernel prevents sharing of information across diseases, we tested dif-
ferent variants to share information including a generic multitask kernel and kernels taking into account
the phenotypic similarity between diseases. We demonstrated the relevance of using the phenotypic sim-
ilarity, compared to the generic multitask kernel, and have enhanced it by the addition of a Dirac kernel.
Given the influence of the disease kernel on the final performance of the method, we believe that there is
still much room for improvement in the design of the prior, using the general ProDiGe framework. We
note in particular that if other descriptors were available for phenotypes, one could also integrate these
data and the prior they induce on task relatedness in the disease kernel.
A important question in practice is to choose between the two variants. We have seen that ProDiGe1
has higher recall in the top 1 or 2% of the list, while ProDiGe4 is better after. Hence a first criterion
to chose among them is the rank level that we are ready to investigate. In addition, one could think
that ProDiGe1, which can not be used for orphan disease, is more generally handicapped compared to
ProDiGe4 when the number of known disease genes is small, while it is in a better situation when many
genes are already known. Indeed, if enough causal genes are known for a given disease, there is intuitively
no need to borrow information from other diseases, which may mislead the prediction. This dependency
of the relative performance of a local and a global approach on the number of training samples has
previously been observed in other contexts [21] where a global approach was shown to bring tangible
improvements over a local one when the number of positive examples was low. We have however checked
for the presence of such an effect, and found that it could not be brought to light, as illustrated in Figure
7 which plots the mean and standard deviation of the rank of the left-out gene in LOOCV as a function
of the number of known genes of the disease during training. We observe no trend indicating that the
performance increases with the number of training genes, and no different behaviour between the local
and multitask approaches, as long as at least one disease gene is known. This surprising finding, which is
coherent with the observation that there is no big difference in performance for orphan and non-orphan
diseases, suggests that the number of known disease genes in not a relevant criterion to choose between
the local and multitask version of ProDiGe. Instead, we suggest in practice to use the local version
ProDiGe 1 if we are interested only in genes ranked in the very top of the candidate gene lists (below the
top 1%), and ProDiGe 4 as soon as we can afford going deeper in the list.
Finally, except for the work of [27], the PU learning point of view on this long-studied gene prioriti-
zation problem is novel. Classical one-class approaches which learn a scoring function to rank candidate
genes using known disease genes only are prone to over-fitting in large dimensions when the training
set if small, which results in poor performance. We observed that our PU learning strategy, augmented
by a multitask point of view to share information across diseases, was useful to obtain better results in
the disease gene identification task. In fact, learning from positive and unlabeled examples is a common
situation in bioinformatics, and PU learning methods combined or not with multitask kernels have a good
potential for solving many problems such as pathway completion, prioritization of cancer patients with a
higher risk of relapse, or prediction of protein-protein or protein-ligand interactions.
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Figure 7: Effect of the number of related genes on the performance.
Material and Methods
The gene prioritization problem
Let us first formally define the disease gene prioritization problem we aim to solve. We start from a
list of N human genes G = {G1, . . . , GN}, which typically can be the full human genome or a subset of
interest where disease genes are suspected. A multitude of data sources to characterize these genes are
given, including for instance expression profiles, functional annotation, sequence properties, regulatory
information, interactions, literature data, etc... We assume that for each data source, each gene G ∈ G is
represented by a finite- or infinite-dimensional vector Φ(G), which defines an inner product K(G,G′) =
Φ(G)⊤Φ(G′) between any two genes G and G′. K is called a kernel in the machine learning community
[28]. Intuitively, K(G,G′) may be thought of as a measure of similarity between genes G and G′ according
to the representation defined by Φ. Since several representations are available, we assume that L feature
vector mappings Φ1, . . . ,ΦL are available, corresponding to L kernels for genes K1,K2, . . . ,KL. Finally,
we suppose given a collection ofM disorders or disease phenotypes D = {D1, . . . ,DM}. For each disorder
Di, the learner is given a set of genes Pi ⊂ G, which contains known causal genes for this phenotype, and
a set of candidate genes Ui ⊂ G where we want to find new disease genes for Di. Typically Ui can be the
complement set of Pi in G if no further information about the disease is available, or could be a smaller
subset if a short list of candidate genes is given for the disease Di. For each disease Di, our goal is to
retrieve more causal genes for Di in Ui. In practice, we aim at ranking the elements of Ui from the most
likely disease gene to the less likely, and we assess the quality of a ranking by its capacity to rank the
true disease genes at or near the top of the list.
Gene prioritization for a single disease and a single data source
Let us first describe our gene prioritization approach ProDiGe for a single disease (M = 1) and a single
data source (L = 1). In that case, we are given a single list of disease genes P ⊂ G, and must rank the
candidate genes in U ⊂ G using the kernel K. As explained in the Introduction, most existing approaches
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define a scoring function s : U → R, using only positive examples in P , to quantify how similar a gene G
in U is to the known disease genes in P . Here we propose to learn the scoring function s(.) both from P
and U , by formulating the problem as an instance of PU learning.
Intuitively, the motivation behind PU learning is to exploit the information provided by the distribu-
tion of unlabeled examples to improve the scoring function, as illustrated in Figure 1. Here we initially
have a set of positive examples (genes known to be related to a given disease for instance) which are
represented on the graph by blue crosses, and we want to retrieve more of them. Traditional approaches
which define a scoring function from P usually try to estimate the support of the positive class distribu-
tion to define an area of “similar genes”, which could be in that case delimited by the dashed line. Now
suppose that we additionally observe a set of unlabeled examples (candidate genes), represented by U
letters. Green Us are positive unlabeled and red ones are negative unlabeled, but this information is not
available. Then, we can have the feeling that the boundary should rather be set in the low density area as
represented by the solid line, which better captures reality than the dashed line. Consequently, using the
distribution of U in addition to the positive examples can help us better characterize the area of positive
examples. This is particularly true in high dimension with few examples, where density estimation from
a few positive examples is known to be very challenging.
Figure 8: An intuitive example of how the unlabeled examples could be helpful.
In practice, a simple and efficient strategy to solve a PU learning problem is to assign negative labels
to elements in U , and train a binary classifier to discriminate P from U , allowing errors in the training
labels. Assuming that the binary classifier assigns a score to each point during training (which is the case
of, e.g., logistic regression or SVM), the score of an element in U is then just the scored assigned to it by
the classifier after training. This approach is easy to implement and it has been shown that building a
classifier that discriminates the positive from the unlabeled set is a good proxy to building a classifier that
discriminates the positive from the negative set. When the binary classifier used is a SVM, this approach
leads to the biased SVM of [16], which was recently combined with bagging to reach faster training time
and equal performance [18]. In practice, the biased SVM over-weights positive examples during training
to account for the fact that they represent high-confidence examples whereas the “negative” examples
are known to contain false negatives, namely, those we hope to discover. Here we use the variant of [18],
which adds a bootstrap procedure to biased SVM. The additional bagging-like feature takes advantage of
the contaminated nature of the unlabeled set, allowing to reach the same performances while increasing
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both speed and scalability to large datasets. The algorithm takes as input a positive and an unlabeled
set of examples, and a parameter B specifying the number of bootstrap iterations. It discriminates the
positive set from random subsamples of the unlabeled set and aggregates the successive classifiers into
a single one (bootstrap aggregating). The output is a score function s such that for any example G,
s(G) reflects our confidence that G is a positive example. We then rank elements in U by decreasing
score. For more details on the method, we refer the reader to [18]. In practice, we implement the SVM
with the libsvm implementation [29]. After observing in preliminary experiments that the regulariza-
tion parameter C of the SVM did not dramatically affect the final performance, we set it constant to
the default value C = 1 for all results shown below. The number of bootstrap iterations was set to B = 30.
Gene prioritization for a single disease and multiple data sources
When several data sources are available to characterize genes, e.g., gene expression profiles and sequence
features, we extend our PU learning method to learn simultaneously from multiple heterogeneous sources
of data through kernel data fusion [24]. Formally, each data source is encoded in a kernel function,
resulting in L ≥ 1 kernels K1, . . . ,KL. We investigate the following two strategies to fuse the L data
sources.
First, we simply define a new kernel which integrates the information contained in all kernels as the
mean of the L kernels, i.e., we define:
Kint =
1
L
L∑
i=1
Ki . (1)
In other words, the kernel similarity Kint(G,G
′) between two genes is defined as the mean similarity
between the two genes over the different data sources. This simple approach is widely used and often
leads to very good performance with SVM to learn classification models from heterogeneous information
[22,30,31]. In our setting, we simply use the integrated kernel (1) each time a SVM is trained in the PU
learning algorithm described in Section , to estimate a prioritization score from multiple data sources.
Alternatively, we test a method for multiple kernel learning (MKL) proposed by [24, 32], which
amounts to building a weighted convex combination of kernels of the form
KMKL =
1
L
L∑
i=1
βiKi , (2)
where the non-negative weights βi are automatically optimized during the learning phase of a SVM.
By weighting differently the various information sources, the MKL formulation can potentially discard
irrelevant sources or give more importance to gene descriptors with more predictive power. Again,
combining MKL with our PU learning strategy described in Section is straightforward: we simply use
the MKL formulation of SVM instead of the classical SVM each time a SVM is trained.
Gene prioritization for multiple diseases and multiple data sources
When multiple diseases are considered, a first option is to treat the diseases independently from each
other, and apply the gene prioritization strategy presented in Sections and to each disease in turn.
However, it is known that disease genes share some common characteristics [27,33,34], and that similar
diseases are often caused by similar genes [5,9,11–14]. This suggests that, instead of treating each disease
separately, it may be beneficial to consider them jointly and share information of known disease genes
across diseases. By mutualizing information across diseases, one may in particular attempt to prioritize
genes for orphan diseases, with no known causal gene. This is an important property since these diseases
are obviously those for which predictions are the most needed.
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We propose to jointly solve the gene prioritization problem for different diseases by formulating
it as a multitask learning problem, and we adapt the multitask learning strategy of [19] to our PU
learning framework. In this setting, instead of just learning a scoring function over individual genes
G ∈ G to rank candidates for a disease, we learn a scoring function over disease-gene pairs of the form
(D,G) ∈ D × G. In order to learn this scoring function, instead of starting from a set of positive
examples P ⊂ G made of known disease genes for a particular disease, we start from a set of positive
pairs
(
Dd(i), Gg(i)
)
i=1,...,T
⊂ D × G obtained by combining the pairs where gene Gg(i) is known to be a
disease gene for disease Dd(i). T is then the total number of known disease-gene pairs. Given the training
set of disease-gene pairs, we then learn a scoring function s over D × G using our general PU learning
algorithm described in Section , where the kernel function between two disease-gene pairs (D,G) and
(D′, G′) is of the form:
Kpair
(
(D,G), (D′, G′)
)
= Kdisease(D,D
′)×Kgene(G,G
′) . (3)
In this equation, Kgene is a kernel between genes, typically equal to one of the kernels described in Sections
and in the context of gene prioritization for a single disease. Kdisease is a kernel between diseases, which
allows sharing of information across diseases, as in classical multitask learning with kernels [19–21].
More precisely, we consider the following variants for Kpair, which give rise to various gene prioritization
methods:
• The Dirac kernel is defined as
KDirac(D,D
′) =
{
1 if D = D′,
0 otherwise.
(4)
Plugging the Dirac kernel into (3), we see that the pairwise kernel between two disease-gene pairs
for different diseases is 0. One can then show that there is no sharing of information across diseases,
and that learning over pairs in this context boils down to treating each disease independently from
the others [19–21]. This is thus our baseline strategy, which treats each disease in turn, and does
not provide a solution for orphan diseases. We call this method ProDiGe1 below.
• The multitask kernel is defined by
Kmultitask(D,D
′) = 1 +KDirac(D,D
′) . (5)
This kernel, which was proposed by [19], allows a basic sharing of information across diseases.
In addition to the genes known to be causal for a disease of interest through the Dirac kernel,
the addition of a constant in (5) allows all other known disease genes for other diseases to play
the role of positive training examples, although to a lesser extent than the disease genes for the
disease of interest. Here we do not use any specific knowledge about the different diseases and their
similarity, and simply try to capture properties that may be shared by disease genes in general.
This corresponds to a low information prior because a disease equally exploits knowledge about all
other diseases. We call this variant ProDiGe2 below.
• The phenotype kernel is an attempt to capture phenotypic similarities between diseases to control the
sharing of information across diseases. Indeed, many previous works have used as prior knowledge
the fact that similar phenotypes are likely to be caused by similar genes [5,9,11–14,35]. This suggests
that, instead of sharing information uniformly across diseases as the multitask kernel (5) does, it
may be beneficial to do it in a more principled way. In particular, the more similar two diseases are,
the more they should share information. In practice, this is obtained by defining a kernel Kphenotype
between diseases that measures their phenotypic similarity, and plugging it into the general pairwise
kernel (3). Here we propose to use the phenotypic similarity measure for diseases based on text
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mining proposed by [36]. Since this measure is derived as a correlation measure, the matrix whose
entries contain the pairwise similarity measures is eligible for kernel learning. We call the resulting
gene prioritization method ProDiGe3 below.
• The phenotype+Dirac kernel. Finally, we propose a slight variant to the phenotype kernel by adding
to it the Dirac kernel:
KP+D(D,D
′) = Kphenotype(D,D
′) +KDirac(D,D
′) . (6)
The motivation for this kernel is that, since the description of disease phenotypes we use to build
Kphenotype is incomplete and does not fully characterize the disease, it may occur that two different
diseases, with different disease genes, have similar or even identical phenotypic description. In this
case, the addition of the Dirac kernel in (6) allows to still distinguish different diseases, and give
more importance to the genes associated to the disease of interest than to the genes associated
to different diseases with similar phenotypes. We call ProDiGe4 the resulting gene prioritization
method.
In summary, each of the four kernels for diseases presented above can be plugged into (3) to define a
kernel for disease-gene pairs. Then, the PU learning strategy presented in Section can be applied to learn
a scoring function over D×G. Finally, the ranking of candidate genes in Ui for a particular disease Di is
obtained by decreasing score s(Di, G) for G ∈ Ui. We thus obtain four variants summarized in Table 6.
When heterogeneous sources of information for genes are available, the two strategies proposed in
Section can be easily combined with each of the four ProDiGe variants, since each particular gene kernel
translates into a particular disease-gene kernel through (3). In the experiments below, we only imple-
ment the MKL approach for ProDiGe1 to compare it to the mean kernel strategy. For other variants of
ProDiGe, we restrict ourselves to the simplest strategy where the different information sources are fused
through kernel averaging.
Experimental setting
We assess the performance of various gene prioritization methods by leave-one-out cross-validation (LOOCV)
on the dataset of known disease-gene association extracted from the OMIM database. Given the list of all
disease-gene associations (Dd(i), Gg(i))i=1,...,T in OMIM, we remove each pair (Dd(i), Gg(i)) in turn from
the training set, train the scoring function from the T − 1 remaining positive pairs, rank all genes G not
associated to Dd(i) in the training set by decreasing score s(Dd(i), G), and check how well Gg(i) is ranked
in the list. Note that in this setting, we implicitly assume that the candidate genes for a disease are all
genes not known to be associated to the disease, i.e., Ui = G\Pi. In the LOOCV setting, each time a
pair (Dd(i), Gg(i)) is removed from the training set, the ranking is then performed on Ud(i) ∪ {Gg(i)}. We
monitor the success of the prioritization by the rank of Gg(i) among candidate genes in Ud(i). Since we are
doing a LOOCV procedure, the rank of the left-out sample is directly related to the classical area under
the Receiver Operating Characteristics curve (AUC), via the formula rank = (|U | + 1) × (1 − AUC).
Therefore, an easy way to visualize the performance of a gene prioritization method is to plot the empiri-
cal cumulative distribution function (CDF) of the ranks obtained for all associations in the training set in
the LOOCV procedure. For a given value of the rank k, the CDF at level k is defined as the proportion of
associations Dd(i), Gg(i) for which gene Gg(i) ranked among the top k in the prioritization list for disease
Dd(i), which can also be called the recall as a function of k.
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Other gene prioritization methods
We compare ProDiGe to two state-of-the-art gene prioritization methods. First we consider the 1-SVM
L2-MKL from [10], which extends and outperforms the Endeavour method [10], and which we denote
MKL1class below. This method performs one-class SVM [37] while optimizing the linear combination of
gene kernels with a MKL approach in the same time. We downloaded a Matlab implementation of all
functions from the supplementary information website of [10]. We used as input the same 9 kernels as
for ProDiGe, and we set the regularization parameter of the algorithm ν = 0.5, as done by [10]. Second,
we compare ProDiGe to the PRINCE method introduced by [14], which is designed to share information
across the diseases. Prior information consists in gene labels that are a function of their relatedness to
the query disease. They are higher for genes known to be directly related to the query disease, high
but at a lesser extent for genes related to a disease which is very similar to the query, smaller for genes
related to a disease that bears little similarity to the query and zero for genes not related to any disease.
PRINCE propagates these labels on a PPI network and produces gene scores that vary smoothly over
the network. We used the same PPI network for PRINCE as the one used by ProDiGe.
Data
The first type of data required by ProDiGe is the description of the set G of human genes. We borrowed
the dataset of [7], based on Ensembl v39 and which contains multiple data sources. We removed genes
whose ID had a “retired” status in Ensembl v59, leaving us with 19540 genes. These genes are described
by microarray expression profiles from [38] and [39] (MA1, MA2), expressed sequence tag data (EST),
functional annotation (GO) , pathway membership (KEGG), protein-protein interactions from the Hu-
man Protein Reference Database (PPI), transcriptional motifs (MOTIF), protein domain activity from
InterPro (IPR) and literature data (TEXT). For PPI data which consists in a graph of interactions, a
diffusion kernel with parameter 1 was computed to obtain a kernel for genes [40]. All other data sources
provide a vectorial representation of a gene. The inner product between these vectors defines the kernel
we create from each data source. All kernels are normalized to unit diagonal to ensure that kernel values
are comparable between different data sources, using the formula:
K˜(G,G′)←
K(G,G′)√
K(G,G) ×K(G′, G′)
. (7)
Second, to define the phenotype kernel between diseases we borrow the phenotypic similarity measure
of [36]. The measure they propose is obtained by automatic text mining. A disease is described in
the OMIM database by a text record [25]. In particular, its description contains terms from the Mesh
(medical subject headings) vocabulary. [36] assess the similarity between two diseases by comparing the
Mesh terms content of their respective record in OMIM. We downloaded the similarity matrix for 5080
diseases from the MimMiner webpage.
Finally, we collected disease-gene associations from the OMIM database [25], downloaded on August
8th, 2010. We obtained 3222 disease-gene associations involving 2606 disorders and 2182 genes.
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Prostate cancer Gastric cancer
CDKN2A(1029) 210 1 EGFR(1956) 853 1
AKT1(207) 1058 1 AKT1(207) 272 0
IGF1R(3480) 152 1 EXT1(2131) 4 0
MSX1(4487) 5 0 FAS(355) 180 0
PAX3(5077) 2 0 LRP5(4041) 8 0
CCND1(595) 372 1 MSX1(4487) 3 0
BRAF(673) 22 1 CCND1(595) 250 1
TP53(7157) 1378 1 BRAF(673) 32 1
WFS1(7466) 0 0 TP53(7157) 1593 1
WT1(7490) 37 1 WFS1(7466) 0 0
Colorectal cancer Leukemia acute myeloid
CDKN2A(1029) 415 1 AKT1(207) 233 0
EXT1(2131) 14 0 FAS(355) 136 0
IGF1R(3480) 86 1 KRAS(3845) 457 1
SMAD4(4089) 211 1 LYN(4067) 26 0
MLH1(4292) 4064 1 MYC(4609) 381 0
PDGFRA(5156) 19 1 RAF1(5894) 30 1
PDGFRB(5159) 45 1 STAT3(6774) 95 0
BRAF(673) 430 1 STK11(6794) 2 0
WFS1(7466) 0 1 BTK(695) 6 0
WT1(7490) 15 0 TP53(7157) 474 1
Diabetes mellitus Breast cancer
COL1A1(1277) 4 0 CDKN2A(1029) 572 1
COL2A1(1280) 6 0 COL2A1(1280) 9 0
CYP3A5(1577) 5 0 COL3A1(1281) 1 0
EXT1(2131) 20 1 EXT1(2131) 22 0
GHR(2690) 49 0 LRP5(4041) 51 0
ABCC6(368) 43 0 MSX1(4487) 10 0
LEP(3952) 754 1 PAX3(5077) 6 0
LRP5(4041) 58 0 PITX2(5308) 310 1
CACNA1S(779) 4 0 BRAF(673) 37 1
ADIPOQ(9370) 1635 1 WFS1(7466) 4 0
Alzheimer Schizophrenia
COL2A1(1280) 0 0 COL1A1(1277) 0 0
CYP1B1(1545) 0 0 COL2A1(1280) 0 0
EXT1(2131) 4 1 ATN1(1822) 40 0
ALDH3A2(224) 4 0 EXT1(2131) 20 0
APOE(348) 4143 1 FGFR3(2261) 78 0
ABCC6(368) 10 0 GJB1(2705) 0 0
LRP5(4041) 3 0 ABCC6(368) 7 0
MAOA(4128) 5 1 LRP5(4041) 4 0
PSEN2(5664) 635 1 PARK2(5071) 1 0
WFS1(7466) 1 0 WFS1(7466) 5 0
Table 5: The top ten genes for 8 diseases with a reasonable training set are scanned. These
diseases are in order: prostate cancer [MIM 176807], colorectal cancer [MIM 114500], diabetes mellitus
[MIM 125853], Alzheimer [MIM 104300], gastric cancer [MIM 137215], leukemia acute myeloid [MIM
601626], breast cancer [MIM 114480], schizophrenia [MIM 181500]. Using GeneValorization, we counted
the number of publication hits in NCBI which are found to be relevant to a query disease and a query
gene. At last, the third column indicates whether the gene belongs to the list extracted from the Ingenuity
Pathways Analysis tool.
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Name Disease kernel Sharing of disease gene information across diseases
Prodige1 KDirac No sharing.
Prodige2 1 +KDirac Uniform sharing.
Prodige3 Kphenotype Sharing weighted by phenotypic similarity.
Prodige4 KDirac +Kphenotype Sharing weighted by phenotypic similarity and disease identity.
Table 6: Summary of ProDiGe variants. We propose four variants, which differ in the way they
share information across diseases, as summarized in the third column of the table. The second column
shows the kernel for diseases used by each variant to achieve the sharing of information. Apart from the
choice of disease kernel, the four variants follow exactly the same procedure described in Section .
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